Biotech company Q BioMed has landed a contract to supply its Strontium89 (strontium-89 chloride injection) metastatic bone cancer palliation radiopharmaceutical to the U.S. Department of Defense (DOD) and the Department of Veterans Affairs (VA).
The five-year Federal Supply Schedule contract took effect on March 1 and provides U.S. veterans and other federal government agencies access to Strontium89 for eligible patients, according to the company. The firm said it will serve the VA and DOD with activities that include a VA sales force, formulary and market access, medical education, and marketing. These efforts will build up over the course of 2021 as clinical use begins, according to Q BioMed.
